Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer.

Background: Currently, serum PSA is the most commonly used screening tool in clinical practice. However, PSA levels in the range of 4-10 ng/ml are considered the 'grey zone' of prostate cancer screening. Patients within this range need to be further evaluated using additional parameters such as PSA ratio, PSA density, and other indices to determine the necessity of prostate biopsy (PBx).